Clinical Trial

Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Based on the detection technology of methylation sites in feces, combined or not combined with Helicobacter pylori gastric cancer susceptibility gene detection, an early diagnosis and detection system for gastric cancer is established, and the clinical diagnostic value of the detection system is evaluated. In addition, the study observed the association between different loci and post-treatment recurrence, metastasis, or long-term survival rate through long-term follow-up of gastric cancer patients; Follow up with individuals with benign diseases such as gastritis and healthy individuals, compare cases of gastric cancer, and compare their sample data during follow-up with controls who did not have the disease.
Trial Details
NCT Number NCT07312500
Lead Sponsor Fudan University
Conditions Gastric (Stomach) Cancer
Enrollment 3,000 participants
Start Date 2025-01-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31